Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meperidine SCHEMBL1083668 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL41046 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL194412 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL25431 | 0.99 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL28905219 | 0.97 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL27945061 | 0.97 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL28695347 | 0.96 | OPRM1 (0.94) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL3054250 | 0.96 | OPRM1 (0.94) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Ethoheptazine SCHEMBL24581 | 0.93 | OPRM1 (0.90) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL12574647 | 0.89 | OPRM1 (0.82) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139525-B2 | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2015-09-22 | — | — | US | disclosed |
| EP-2146961-B1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | IVAX INT GMBH (CH) | 2014-01-29 | — | — | EP | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| EP-2146961-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008127188-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | ALLBAY AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| US-4990617-A | Analgesics, narcotic antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-02-05 | — | — | US | disclosed |
| US-4722928-A | N-OXIDES OF NALBUPHINE, NALTREXONE AND NALOXONE; ANALGESICS, APPETITE DEPRESSANTS, NARCOTIC ANTAGONIST | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | CHRM4, GPR4, HTR4 | OPRM1 82/4885OPRD1 87/4885OPRK1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.